RxDoctor Payments Data

Emmanuel Gorospe

Gastroenterology · El Paso, TXNPI 1225160427

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,000 of the $4,523 with a category attached, or 66.3%. Eli Lilly accounts for 66.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2022 at $3,401 and has fallen 99.5% since, to $17 in 2023.

$4,523in general payments, 2019–2025

Across 55 payments — averaging $82.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3K
  • Ambu Inc.$527
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$272
  • Takeda Pharmaceuticals U.S.A., Inc.$136
  • Novartis$92
  • Biogen$73
  • plus $423 from 13 others
$2,282,964in research payments, 2019–2025

Across 114 payments — averaging $20,026 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$1.5M
  • Amgen$677K
  • Regeneron$70K
  • Bausch Health US, LLC$32K
  • GSK$19K

What the payments were for

  • Consulting fees$3,00066%
  • Food & beverage$1,52334%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,523 in reported general payments places this provider in the 55th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Other gastroenterology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →